8 research outputs found
OEDIPE, a software for personalized Monte Carlo dosimetry and treatment planning optimization in nuclear medicine Absorbed dose and biologically effective dose considerations
International audienceFor targeted radionuclide therapies, treatment planning usually consists of the administration of standard activities without accounting for the patient-specific activity distribution, pharmacokinetics and dosimetry to organs at risk. The OEDIPE software is a user-friendly interface which has an automation level suitable for performing personalized Monte Carlo 3D dosimetry for diagnostic and therapeutic radionuclide administrations. Mean absorbed doses to regions of interest (ROIs), isodose curves superimposed on a personalized anatomical model of the patient and dose-volume histograms can be extracted from the absorbed dose 3D distribution. Moreover, to account for the differences in radiosensitivity between tumoral and healthy tissues, additional functionalities have been implemented to calculate the 3D distribution of the biologically effective dose (BED), mean BEDs to ROIs, isoBED curves and BED-volume histograms along with the Equivalent Uniform Biologically Effective Dose (EUD) to ROIs. Finally, optimization tools are available for treatment planning optimization using either the absorbed dose or BED distributions. These tools enable one to calculate the maximal injectable activity which meets tolerance criteria to organs at risk for a chosen fractionation protocol. This paper describes the functionalities available in the latest version of the OEDIPE software to perform personalized Monte Carlo dosimetry and treatment planning optimization in targeted radionuclide therapies. © 2014 EDP Sciences
Fractionation protocol design for treatment planning optimization in SIRT using the OEDIPE software
To go further in the optimization of treatment planning in selective internal radiation
therapy (SIRT), radiobiological aspects can be accounted for with the OEDIPE software and
used to design fractionation protocols. Dosimetry was performed using data from
99mTc-MAA
evaluations of 10 patients treated for hepatic metastases with SIRT. The maximal
injectable activity (MIA) was calculated, using a tolerance criterion on
BEDmean,healthyliver equal to 54 Gy2.5, for different fractionation
protocols, varying the number of fractions, the repartition of activity and the time delay
between fractions. OEDIPE was also used to calculate BEDmean and the EUD to the tumoral
liver (TL) that would be delivered with those MIAs. Compared with a single-injection
protocol, the MIA is increased on average by 23% ± 3%, 36% ± 5% and 45% ± 7% for fractionation protocols with 2, 3
and 4 equal fractions, respectively, while BEDmean,TL is increased by 15% ± 2%, 23% ± 4% and 29% ± 5%. EUDTL, calculated for one
evaluation, is increased by 51%, 115% and 159% using 2, 3 and 4 equal fractions,
respectively. For this evaluation, the optimal activity repartition for two-fraction
protocols is (3/4 − 1/4) for
time delays of less than 4 days, (2/3 − 1/3) for time delays between 4 and 6 days and (1/2 − 1/2) for time delays superior to 6 days.
Finally, this study confirmed that OEDIPE can be regarded as a tool for treatment planning
optimization and fractionation protocol design in SIRT
Liver Selective Internal Radiation Therapy with 90Y resin microspheres Comparison between pre-treatment activity calculation methods
International audienceDifferent methods to calculate 90Y resin microspheres activity for Selective Internal Radiation Therapy (SIRT) were compared. Such comparison is not yet available and is needed in clinical practice to optimize patient specific treatment planning.32 99mTc-macroagregates (MAA) evaluations were performed, followed by 26 treatments. Four methods to calculate 90Y-activity were applied retrospectively three based on Body Surface Area and one based on MIRD formalism, partition model (PM). Relationships between calculated activities, lung breakthrough (LB), the activity concentration ratio between lesions and healthy liver (T/N) and tumour involvement were investigated, where lobar and whole liver treatments were analysed separately.Without attenuation correction, overestimation of LB was 65%. In any case, the estimated lungs' doses remained below 30Gy. Thus, the maximal injectable activity (MIA) is not limited by lungs' irradiation. Moreover, LB was not significantly related to T/N, neither to tumour involvement nor radiochemical purity (RP).Differences in calculated activity with the four methods were extremely large, in particular they were greater between BSA-based and PM activities for lobar treatments (from-85% to 417%) compared to whole liver treatments (from-49% to 61%). Two values of T/N ratio were identified as thresholds for BSA-based methods, healthy liver doses are much higher than 30Gy when T/Nandlt;3; for PM, tumour doses are higher than 120Gy when T/N andgt; 4. As PM accounts for uptake ratio between normal and tumour liver, this method should be employed over BSA-based methods. © 2014 Associazione Italiana di Fisica Medica
Three-dimensional personalized monte carlo dosimetry in 90y resin microspheres therapy of hepatic metastases Nontumoral liver and lungs radiation protection considerations and treatment planning optimization
International audienceIn the last decades, selective internal radiation therapy (SIRT) has become a real alternative in the treatment of unresectable hepatic cancers. In practice, the activity prescription is limited by the irradiation of organs at risk (OAR), such as the lungs and nontumoral liver (NTL). Its clinical implementation is therefore highly dependent on dosimetry. In that context, a 3-dimensional personalized dosimetry technique-personalized Monte Carlo dosimetry (PMCD)- based on patient-specific data and Monte Carlo calculations was developed and evaluated retrospectively on clinical data. Methods The PMCD method was evaluated with data from technetium human albumin macroaggregates (99mTc-MAA) evaluations of 10 patients treated for hepatic metastases. Region-of-interest outlines were drawn on CT images to create patient-specific voxel phantoms using the OEDIPE software. Normalized 3-dimensional matrices of cumulated activity were generated from 99mTc-SPECT data. Absorbed doses at the voxel scale were then obtained with the MCNPX Monte Carlo code. The maximum-injectable activity (MIA) for tolerance criteria based on either OAR mean absorbed doses (D mean) or OAR dose-volume histograms (DVHs) was determined using OEDIPE. Those MIAs were compared with the one recommended by the partition model (PM) with Dmean tolerance criteria. Finally, OEDIPE was used to evaluate the absorbed doses delivered if those activities were injected to the patient and to generate the corresponding isodose curves and DVHs. Results The MIA recommended using Dmean tolerance criteria is, in average, 27% higher with the PMCD method than with the PM. If tolerance criteria based on DVHs are used along with the PMCD, an increase of at least 40% of the MIA is conceivable, compared with the PM. For MIAs calculated with the PMCD, D mean delivered to tumoral liver (TL) ranged from 19.5 to 118 Gy for Dmean tolerance criteria whereas they ranged from 26.6 to 918 Gy with DVH tolerance criteria. Thus, using the PMCD method, which accounts for fixation heterogeneities, higher doses can be delivered to TL. Finally, absorbed doses to the lungs are not the limiting criterion for activity prescription. However, Dmean to the lungs can reach 15.0 Gy. Conclusion Besides its feasibility and applicability in clinical routine, the interest for treatment optimization of a personalized Monte Carlo dosimetry in the context of SIRT was confirmed in this study. © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc